Meyer Handelman Co. Lowers Stock Position in Bristol Myers Squibb Company $BMY
Meyer Handelman Co. lessened its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 4. 4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 412,364 shares of the biopharmac
Meyer Handelman Co. lessened its stake in Bristol Myers Squibb Company (NYSE:BMY-Free Report) by 4. 4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 412,364 shares of the biopharmaceutical company's stock after selling 18,801 shares during the period. Meyer Handelman Co. 's holdings in Bristol Myers Squibb were worth $23,760,000 at the end of the most recent reporting period. 2 Buffett Stocks to Load Up On—And 1 to DitchOther institutional investors and hedge funds have also recently made changes to their positions in the company. Swiss RE Ltd. bought a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $25,000. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb in the second quarter valued at $25,000. Physician Wealth Advisors Inc. raised its position in Bristol Myers Squibb by 73. 5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 202 shares in the last quarter. Bayban purchased a new stake in Bristol Myers Squibb during the fourth quarter valued at about $31,000. Finally, EQ Wealth Advisors LLC bought a new stake in Bristol Myers Squibb during the fourth quarter worth about $32,000. Hedge funds and other institutional investors own 76. 41% of the company's stock. GetBristol Myers Squibbalerts:Bristol Myers Squibb Stock PerformanceNYSE BMYopened at $63. 86 on Friday. The company has a 50-day simple moving average of $59. 56 and a two-hundred day simple moving average of $58. 97. Bristol Myers Squibb Company has a 12-month low of $42. 52 and a 12-month high of $68. 10. The firm has a market cap of $130. 45 billion, a price-to-earnings ratio of 14. 07, a PEG ratio of 0. 17 and a beta of 0. 22. The company has a quick ratio of 1. 38, a current ratio of 1. 53 and a debt-to-equity ratio of 1. 89. Why GRAIL Stock Could Be Biotech’s Next Big BreakoutBristol Myers Squibb (NYSE:BMY-Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2. 04 EPS for the quarter, topping the consensus estimate of $1. 60 by $0. 44. Bristol Myers Squibb had a return on equity of 66. 90% and a net margin of 18. 87%. The firm had revenue of $12. 97 billion for the quarter, compared to the consensus estimate of $11. 74 billion. During the same quarter in the previous year, the business earned $1. 46 earnings per share. The company's quarterly revenue was up 5. 7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6. 750-7. 000 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6. 96 EPS for the current year. Bristol Myers Squibb Announces DividendThe business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a $0. 63 dividend. This represents a $2. 52 dividend on an annualized basis and a yield of 3. 9%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb's payout ratio is 55. 51%. Analyst Ratings ChangesDon’t Be Fooled by the Bounce: The Market Storm Isn’t Over YetA number of equities analysts have recently issued reports on BMY shares. Jefferies Financial Group cut Bristol Myers Squibb from a "buy" rating to a "hold" rating in a report on Wednesday, August 5th. BMO Capital Markets reissued a "market perform" rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Piper Sandler started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued an "overweight" rating for the company. Weiss Ratingsupgraded shares of Bristol Myers Squibb from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, July 30th. Finally, Raymond James Financial initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "strong-buy" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat. com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $66. 06. Read Our Latest Stock Report on Bristol Myers SquibbMore Bristol Myers Squibb NewsHere are the key news stories impacting Bristol Myers Squibb this week:Positive Sentiment:The U. S. FDA granted accelerated approval toZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from CelgenePositive Sentiment:Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6. 20 from $5. 93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum. Positive Sentiment:The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal studyNeutral Sentiment:Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamergerNegative Sentiment:A federal appeals court revived a $6. 7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revivedBristol Myers Squibb Company Profile(Free Report)Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics. BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions. See AlsoFive stocks we like better than Bristol Myers SquibbMarketBeat Week in Review – 08/10 - 08/14Sony and TSMC’s $4. 7 Billion Venture Is About More Than Camera SensorsQuantum Leaps: Debt-Free as AI Storage Demand AcceleratesNVIDIA's $500 Billion GPU Financing Deal Fuels Path Toward $270Want to see what other hedge funds are holding BMY?Visit HoldingsChannel. comto get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY-Free Report). This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat. com. Continue following MarketBeatAdd MarketBeat as your preferred source on Google to see our latest stories in your feed. Should You Invest $1,000 in Bristol Myers Squibb Right Now?Before you consider Bristol Myers Squibb, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified thefive stocksthat top analysts are quietly whispering to their clients to buy now before the broader market catches on. . . and Bristol Myers Squibb wasn't on the list. While Bristol Myers Squibb currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks HereRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report